Doctors found that Avastin improved the sight of patients suffering from the leading cause of blindness in the elderly, a condition called age-related macular degeneration (AMD).
The drug could cost as little as £350 annually, much less than the £10,000-a-year price tag of the current therapy.
1 comment:
those numbers strike me as inaccurate.
Avastin is a 'mab' which means it's a monoclonal antibody. No monoclonal antibody that I've heard of costs just $500 a year!
To quote the new york time, "Avastin, which can cost as much as $100000 a year"
Post a Comment